Merck’s Keytruda Meets Primary Endpoint in Phase III Ovarian Cancer Trial
US-based Merck Sharp & Dohme Inc. (MSD; NYSE: MRK) announced positive results from the Phase...
Clinical trial results
Innovent Biologics Commences Phase III GLORY-3 Study of Mazdutide for Metabolic Dysfunction-associated Fatty Liver Disease
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the Phase III...
Zhongsheng Pharma’s Anruiwei Shows Promising Results in Pediatric Influenza A Study
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the topline analysis data from the...
BRL Medicine Reports Positive Results for TyU19 in Refractory SLE Trial
Shanghai-based BRL Medicine Inc. announced positive results from an investigator-initiated trial (ITT) evaluating its allogeneic...
Huadong Medicine Presents DR10624 Study Results for Obesity and Hypertriglyceridemia at EASL 2025
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced the first presentation of results from its...
RemeGen’s Disitamab Vedotin Phase III Study Meets PFS and OS Endpoints
China-based RemeGen Ltd (HKG: 9995) announced that its Phase III clinical study for the antibody...
CARsgen Therapeutics’ CT0596 Shows Promising Results in Early Clinical Study
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced preliminary clinical data for CT0596, an allogeneic...
AstraZeneca and Daiichi Sankyo Announce Positive DESTINY-Breast11 Trial Results for Enhertu
Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced the positive preliminary results from...
Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that a filing to conduct a Phase...
Zhongsheng Pharma’s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose...
Innovent Biologics Presents Positive IBI302 Results for nAMD at ARVO 2025
China-based Innovent Biologics, Inc. (HKG: 1801) announced the presentation of 1-year results from its Phase...
AccurEdit Therapeutics’ ART001 Shows Promising Results in ATTR Treatment
China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd. has published the latest data...
AstraZeneca’s Breztri Aerosphere Meets Primary Endpoints in Phase III Asthma Trials
UK-based pharmaceutical firm AstraZeneca (AZ; NASDAQ: AZN) this week unveiled results from the Phase III...
Alphamab and CSPC Announce Positive Interim Results for KN026 in HER2+ Gastric Cancer Trial
China-based firms Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the...
Boehringer Ingelheim’s Zongertinib Shows Promising Results in HER2-Mutant NSCLC Trial
German pharmaceutical giant Boehringer Ingelheim has released the latest results from the Beamion LUNG-1 trial,...
Johnson & Johnson’s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer
US giant Johnson & Johnson (J&J; NYSE: JNJ) has released the first results from Cohort...
BMS’s Cobenfy Shows Promise in Phase III ARISE Trial for Schizophrenia
Bristol-Myers Squibb (BMS, NYSE: BMY) has announced top-line results from the Phase III ARISE trial...
Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment
China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive top-line results from a Phase Ib...
Akeso’s Ivonescimab Shows Strong Results in Phase III Trial for Sq-NSCLC
China-based Akeso, Inc. (HKG: 9926) announced strongly positive results from the regulatory Phase III AK112-306/HARMONi-6...
Grand Pharma’s GPN02006 Shows Promising HCC Diagnostic Results in Trial
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has reported excellent outcomes from the investigator-initiated...